Ensysce Biosciences, Inc. - Common Stock (ENSC)

~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~

~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~

Rapid Dose Therapeutics (CSE: DOSE; OTCQB: RDTCF ), a biotechnology and drug delivery innovation company, is accelerating clinical validation of its proprietary QuickStrip™ oral thin film delivery system through expanded cannabinoid research and a high-profile study supported by the National Football League (NFL) .

~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~

Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~

~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~

~ New ADHD pipeline leverages TAAP™ and MPAR® technologies to improve safety for patients ~

PF614-301 Phase 3 Trial Enrollment Underway, Advancing Toward Market Launch

~ Engineered to Deliver Potent Pain Relief with Unique, Built-In, Abuse Protection ~

~ New U.S. Patent Extends Protection Through 2042 ~

~ FDA Response Streamlines Path to Commercial Production of PF614~

~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~

~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~

~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~

~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~

~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval

~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~

~ FDA Protocol Review Completed ~

~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~

~ Pain Management, RE-Invented: A New Era for Analgesia ~

Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder